Mesa Laboratories Beheer

Beheer criteriumcontroles 2/4

De CEO Mesa Laboratories is Gary Owens, benoemd in Sep2017, heeft een ambtstermijn van 7.17 jaar. De totale jaarlijkse vergoeding van { bedraagt $ 5.44M, bestaande uit 13.9% salaris en 86.1% bonussen, inclusief aandelen en opties van het bedrijf. bezit rechtstreeks 0.8% van de aandelen van het bedrijf, ter waarde $ 4.87M. De gemiddelde ambtstermijn van het managementteam en de raad van bestuur bedraagt respectievelijk 7.2 jaar en 4.5 jaar.

Belangrijke informatie

Gary Owens

Algemeen directeur

US$5.4m

Totale compensatie

Percentage CEO-salaris	13.9%
Dienstverband CEO	7.2yrs
Eigendom CEO	0.8%
Management gemiddelde ambtstermijn	7.2yrs
Gemiddelde ambtstermijn bestuur	4.5yrs

Recente managementupdates

Recent updates

We Think Mesa Laboratories (NASDAQ:MLAB) Can Stay On Top Of Its Debt

Oct 17

A Piece Of The Puzzle Missing From Mesa Laboratories, Inc.'s (NASDAQ:MLAB) 27% Share Price Climb

Jul 29

Is Now An Opportune Moment To Examine Mesa Laboratories, Inc. (NASDAQ:MLAB)?

May 03

Is Mesa Laboratories (NASDAQ:MLAB) Using Too Much Debt?

Mar 15

Mesa Laboratories, Inc. Just Beat Earnings Expectations: Here's What Analysts Think Will Happen Next

Feb 08

Investor Optimism Abounds Mesa Laboratories, Inc. (NASDAQ:MLAB) But Growth Is Lacking

May 31

A Look At The Intrinsic Value Of Mesa Laboratories, Inc. (NASDAQ:MLAB)

Apr 12

Does Mesa Laboratories (NASDAQ:MLAB) Have A Healthy Balance Sheet?

Mar 13

Estimating The Fair Value Of Mesa Laboratories, Inc. (NASDAQ:MLAB)

Dec 20

Mesa Laboratories declares $0.16 dividend

Oct 03

Mesa Laboratories: Softening Bottom Line Fundamentals, Fairly Priced

Sep 09

Are Investors Undervaluing Mesa Laboratories, Inc. (NASDAQ:MLAB) By 41%?

Sep 06

Does Mesa Laboratories (NASDAQ:MLAB) Have A Healthy Balance Sheet?

Aug 08

Mesa Laboratories GAAP EPS of -$0.27 misses by $0.27, revenue of $50.45M misses by $1.72M

Aug 04

Mesa Laboratories declares $0.16 dividend

Jul 07

Analyse CEO-vergoeding

Hoe is Gary Owens's beloning veranderd ten opzichte van Mesa Laboratories's winst?
Datum	Totale vergoeding	Salaris	Bedrijfswinsten
Sep 30 2024	n/a	n/a	-US$246m
Jun 30 2024	n/a	n/a	-US$250m
Mar 31 2024	US$5m	US$754k	-US$254m
Dec 31 2023	n/a	n/a	US$948k
Sep 30 2023	n/a	n/a	-US$717k
Jun 30 2023	n/a	n/a	US$2m
Mar 31 2023	US$5m	US$733k	US$930k
Dec 31 2022	n/a	n/a	-US$1m
Sep 30 2022	n/a	n/a	-US$4m
Jun 30 2022	n/a	n/a	-US$2m
Mar 31 2022	US$18m	US$579k	US$2m
Dec 31 2021	n/a	n/a	US$8m
Sep 30 2021	n/a	n/a	US$5m
Jun 30 2021	n/a	n/a	US$4m
Mar 31 2021	US$3m	US$524k	US$3m
Dec 31 2020	n/a	n/a	-US$2m
Sep 30 2020	n/a	n/a	-US$2m
Jun 30 2020	n/a	n/a	-US$2m
Mar 31 2020	US$3m	US$600k	US$2m
Dec 31 2019	n/a	n/a	US$5m
Sep 30 2019	n/a	n/a	US$10m
Jun 30 2019	n/a	n/a	US$8m
Mar 31 2019	US$3m	US$520k	US$7m
Dec 31 2018	n/a	n/a	US$10m
Sep 30 2018	n/a	n/a	-US$2m
Jun 30 2018	n/a	n/a	-US$249k
Mar 31 2018	US$1m	US$417k	-US$3m

Compensatie versus markt: De totale vergoeding ($USD 5.44M ) Gary } ligt boven het gemiddelde voor bedrijven van vergelijkbare omvang in de US markt ($USD 3.18M ).

Compensatie versus inkomsten: De vergoeding van Gary is gestegen terwijl het bedrijf verliesgevend is.

CEO

Gary Owens (56 yo)

7.2yrs

Tenure

US$5,435,566

Compensatie

Mr. Gary M. Owens has been Chief Executive Officer, President and Director of Mesa Laboratories, Inc. since September 1, 2017. Mr. Owens joined as Chief Operating Officer in March 2017. Mr. Owens served as...

Leiderschapsteam

Naam	Positie	Tenure	Compensatie	Eigendom
Gary Owens	CEO, President & Director	7.2yrs	US$5.44m	0.80% $ 4.9m
John Sakys	VP, CFO & Chief Accounting Officer	12.1yrs	US$1.94m	0.22% $ 1.4m
Brian Archbold	Senior Vice President of Continuous Improvement	6.8yrs	US$1.62m	0% $ 0

7.2yrs

Gemiddelde duur

55yo

Gemiddelde leeftijd

Ervaren management: Het managementteam van MLAB is doorgewinterd en ervaren (gemiddelde ambtstermijn van 7.2 jaar).

Bestuursleden

Naam	Positie	Tenure	Compensatie	Eigendom
Gary Owens	CEO, President & Director	7.2yrs	US$5.44m	0.80% $ 4.9m
Shiraz Ladiwala	Lead Independent Director	3.1yrs	US$220.03k	0.057% $ 345.5k
John Sullivan	Independent Chairman of the Board	15.7yrs	US$255.13k	1.34% $ 8.2m
R. Tripeny	Independent Director	2.4yrs	US$220.13k	0.049% $ 301.1k
Mark Capone	Independent Director	less than a year	US$90.03k	0.013% $ 81.4k
Shannon Hall	Independent Director	4.5yrs	US$220.13k	0.051% $ 313.1k
Jennifer Alltoft	Independent Director	5.7yrs	US$220.13k	0.064% $ 390.5k

4.5yrs

Gemiddelde duur

58yo

Gemiddelde leeftijd

Ervaren bestuur: De raad van bestuur van MLAB wordt beschouwd als ervaren (gemiddelde ambtstermijn 4.5 jaar).

Mesa Laboratories Beheer

Beheer criteriumcontroles 2/4

Belangrijke informatie

Recente managementupdates

CEO, President & Director recently sold US$572k worth of stock

CEO, President & Director notifies of intention to sell stock

Insider notifies of intention to sell stock

Mesa Laboratories, Inc., Annual General Meeting, Aug 30, 2024

Mesa Laboratories, Inc. Appoints Mark Capone to Its Board of Directors

Insider notifies of intention to sell stock

Recent updates

Second quarter 2025 earnings: EPS exceeds analyst expectations

CEO, President & Director recently sold US$572k worth of stock

CEO, President & Director notifies of intention to sell stock

We Think Mesa Laboratories (NASDAQ:MLAB) Can Stay On Top Of Its Debt

First quarter dividend of US$0.16 announced

Mesa Laboratories, Inc. Declares Quarterly Dividend, Payable on December 16, 2024

Insider notifies of intention to sell stock

Price target increased by 10% to US$130

A Piece Of The Puzzle Missing From Mesa Laboratories, Inc.'s (NASDAQ:MLAB) 27% Share Price Climb

Fourth quarter dividend of US$0.16 announced

Mesa Laboratories, Inc., Annual General Meeting, Aug 30, 2024

Mesa Laboratories, Inc. Declares Quarterly Dividend, Payable on September 16, 2024

Mesa Laboratories, Inc. announced delayed annual 10-K filing

Mesa Laboratories, Inc. announced delayed annual 10-K filing

Full year 2024 earnings: Revenues exceed analysts expectations while EPS lags behind

Mesa Laboratories, Inc. Reports Impairment of Goodwill and Long-Lived Assets for the Fourth Quarter Ended March 31, 2024

Upcoming dividend of US$0.16 per share

Is Now An Opportune Moment To Examine Mesa Laboratories, Inc. (NASDAQ:MLAB)?

Third quarter dividend of US$0.16 announced

Mesa Laboratories, Inc. Declares Regular Quarterly Dividend, Payable on June 14, 2024

Mesa Laboratories, Inc. to Report Q4, 2024 Results on May 24, 2024

Is Mesa Laboratories (NASDAQ:MLAB) Using Too Much Debt?

Consensus EPS estimates upgraded to US$0.055 loss

Upcoming dividend of US$0.16 per share

Mesa Laboratories, Inc. Just Beat Earnings Expectations: Here's What Analysts Think Will Happen Next

New minor risk - Earnings quality

Third quarter 2024 earnings: EPS exceeds analyst expectations while revenues lag behind

Mesa Laboratories, Inc. Appoints Mark Capone to Its Board of Directors

Mesa Laboratories, Inc. Declares Regular Quarterly Dividend, Payable on March 15, 2024

Insider notifies of intention to sell stock

Mesa Laboratories, Inc. to Report Q3, 2024 Results on Feb 05, 2024

Is Mesa Laboratories, Inc. (NASDAQ:MLAB) Trading At A 43% Discount?

Upcoming dividend of US$0.16 per share at 0.7% yield

Price target decreased by 17% to US$115

Second quarter 2024 earnings: EPS and revenues miss analyst expectations

Mesa Laboratories, Inc. (NasdaqGS:MLAB) entered into a definitive agreement to acquire Beijing GKE Science & Technology Co. LTD for €5 million.

Mesa Laboratories, Inc. (NasdaqGS:MLAB) acquired Sterilization indicators business of GKE-GmbH and SAL GmbH from Gke-GmbH for €80 million.

Price target decreased by 8.9% to US$139

Mesa Laboratories, Inc. Declares Quarterly Dividend, Payable on December 15, 2023

Is Mesa Laboratories (NASDAQ:MLAB) A Risky Investment?

Mesa Laboratories, Inc. to Report Q2, 2024 Results on Nov 06, 2023

CEO, President & Director notifies of intention to sell stock

Upcoming dividend of US$0.16 per share at 0.5% yield

Estimating The Intrinsic Value Of Mesa Laboratories, Inc. (NASDAQ:MLAB)

First quarter 2024 earnings: EPS and revenues miss analyst expectations

New minor risk - Shareholder dilution

Mesa Laboratories, Inc., Annual General Meeting, Aug 25, 2023

We Think Mesa Laboratories (NASDAQ:MLAB) Is Taking Some Risk With Its Debt

Now 20% undervalued after recent price drop

Mesa Laboratories, Inc. to Report Q1, 2024 Results on Aug 03, 2023

CEO, President & Director exercised options and sold US$166k worth of stock

Consensus EPS estimates increase by 14%

Now 21% undervalued after recent price drop

Investor Optimism Abounds Mesa Laboratories, Inc. (NASDAQ:MLAB) But Growth Is Lacking

Price target decreased by 11% to US$178

Full year 2023 earnings: EPS and revenues miss analyst expectations

Upcoming dividend of US$0.16 per share at 0.4% yield

Mesa Laboratories, Inc. Announces John B. Schmieder, Member of the Board of Directors, Chair of the Nominating and Governance Committee, and Member of the Audit Committee Decide Not to Stand for Re-Election

A Look At The Intrinsic Value Of Mesa Laboratories, Inc. (NASDAQ:MLAB)

VP, CFO & Chief Accounting Officer notifies of intention to sell stock

Does Mesa Laboratories (NASDAQ:MLAB) Have A Healthy Balance Sheet?

VP, CFO & Chief Accounting Officer notifies of intention to sell stock

Upcoming dividend of US$0.16 per share at 0.4% yield

VP, CFO & Chief Accounting Officer exercised options and sold US$132k worth of stock

Third quarter 2023 earnings: EPS and revenues miss analyst expectations

VP, CFO & Chief Accounting Officer exercised options and sold US$293k worth of stock

Independent Director exercised options and sold US$137k worth of stock

Mesa Laboratories, Inc. Declares Quarterly Dividend, Payable on March 15, 2023

Estimating The Fair Value Of Mesa Laboratories, Inc. (NASDAQ:MLAB)